IBEX (IBEX) Form 144: Insider Sale of 1,001 Shares ($39,621)

IBEX Ltd insider Christina Alice Trofimuk-O'Connor filed a Form 144 to sell 1,001 shares of common stock on NASDAQ with an aggregate market value of $39,621.33 and an approximate sale date of 10/02/2025.

Rhea-AI Filing Summary

IBEX Ltd insider Christina Alice Trofimuk-O'Connor filed a Form 144 to sell 1,001 shares of common stock on NASDAQ with an aggregate market value of $39,621.33 and an approximate sale date of 10/02/2025. The filing states these shares were acquired by the filer on 09/30/2025 through the vesting of a performance grant totaling 3,228 shares and shows recent open-market disposals of 366 shares on 08/26/2025 for $10,661.58 and 844 shares on 09/16/2025 for $32,494.00. The filing includes the standard representation that the filer is not aware of undisclosed material adverse information about the issuer.

Positive

• Full disclosure of planned sale—Form 144 reports the intended sale of 1,001 shares and related details
• Source of shares disclosed—shares were acquired by vesting of a performance grant on 09/30/2025
• Recent prior sales disclosed—two open-market sales totaling 1,210 shares are listed with proceeds

Negative

• Insider sell activity—the filing shows insider sales of 1,210 shares in Aug–Sep 2025
• Potential short-term liquidity event—planned sale occurs within days of vesting (09/30/2025 acquisition vs 10/02/2025 sale date)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the IBEX Form 144 filed by Christina Alice Trofimuk-O'Connor disclose?

The filing discloses an intended sale of 1,001 common shares on NASDAQ with an aggregate market value of $39,621.33 and an approximate sale date of 10/02/2025.

How were the shares to be sold by the IBEX insider acquired?

The shares were acquired via the vesting of a performance grant on 09/30/2025, showing 3,228 shares credited on that date.

What prior insider sales are reported in the Form 144 for IBEX?

The filing lists two prior open-market sales: 366 shares on 08/26/2025 for $10,661.58 and 844 shares on 09/16/2025 for $32,494.00.

On which exchange is the planned IBEX sale to occur?

The planned sale is listed to occur on NASDAQ.

Does the filer assert any undisclosed material information in the Form 144?

Yes. The filing includes the standard signed representation that the filer does not know of any material adverse information about the issuer that has not been publicly disclosed.

How many outstanding shares does IBEX report in the Form 144?

The filing lists 13,315,077 shares outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/02/2025 - 05:16 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001973684
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IBEX Ltd
SEC File Number	001-38442
Address of Issuer	1717 PENNSYLVANIA AVENUE NW SUITE 825 WASHINGTON DISTRICT OF COLUMBIA 20006
Phone	(202)580-6200
Name of Person for Whose Account the Securities are To Be Sold	Trofimuk-O'Connor Christina Alice
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	GLOBAL SHARES FINANCIAL SERVICES INC. 575 WASHINGTON BLVD FLOOR 9 JERSEY CITY NJ 07310-1616	1001	39621.33	13315077	10/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	09/30/2025	VESTING OF PERFORMANCE GRANT	ISSUER			3228	09/30/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Christina Alice Trofimuk-O'Connor c/o IBEX LIMITED 1717 Pennsylvania Avenue NW, Suite 825 Washington DC 20006	COMMON	08/26/2025	366	10661.58
Christina Alice Trofimuk-O'Connor c/o IBEX LIMITED 1717 Pennsylvania Avenue NW, Suite 825 Washington DC 20006	COMMON	09/16/2025	844	32494.00

144: Remarks and Signature

Remarks
Date of Notice	10/02/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	POA LISA LENSTROHM
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)